Blockchain Registration Transaction Record

Helus Pharma to Host Investor Webinar on Psychedelic-Inspired Depression and Anxiety Treatments

Helus Pharma to host investor presentation on Oct. 21, 2026, highlighting Phase 3 HLP003 for depression and Phase 2 HLP004 for anxiety. Live webcast and replay available.

This news matters because it highlights a critical juncture in mental health treatment. Major depressive disorder and generalized anxiety disorder affect millions worldwide, and current therapies often fail to provide durable relief. Helus Pharma's NSAs represent a novel approach that could transform the standard of care. With HLP003 in Phase 3 and Breakthrough Therapy Designation, and HLP004 in Phase 2, the company is advancing a pipeline that, if successful, could offer new hope for patients who have not responded to existing treatments. The investor presentation provides a window into this progress, signaling potential for significant clinical and commercial impact. As the mental health crisis escalates, innovations like these are essential, and stakeholders—from patients to investors—should pay close attention.